Korro Bio, Inc. (KRRO): who owns it and who trades it
As of Nov 16, 2026, KRRO insiders reported 39 open-market sales worth $6.7M and 8 purchases worth $3.3M in the last 12 months, with 92% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jean Francois Formela (Director), with $6.1M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Korro Bio
From the latest filingsOverall: more selling than buying. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns KRRO
107 funds and institutions reported KRRO shares worth $199M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Lynx1 Capital Management LP with 10.7%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 1.54M | 10.67% | $20.3M | No change |
| Nantahala Capital Management, LLC | 1.32M | 9.15% | $17.4M | +100% |
| NEA Management Company, LLC | 1.30M | 9.00% | $17.1M | No change |
| Venrock Adviser, LLC | 1.01M | 7.00% | $13.3M | No change |
| Atlas Venture Life Science Advisors, LLC | 962,884 | 6.68% | $12.7M | -15% |
| Balyasny Asset Management L.P. | 951,783 | 6.60% | $12.5M | -8% |
| BlackRock, Inc. | 817,621 | 5.67% | $10.8M | +78% |
| Affinity Asset Advisors, LLC | 706,904 | 4.90% | $9.3M | No change |
| Adage Capital Partners Gp, L.l.c. | 540,968 | 3.75% | $7.1M | +137% |
| ADAR1 Capital Management, LLC | 540,054 | 3.74% | $7.1M | No change |
| Vanguard Capital Management LLC | 454,778 | 3.15% | $6M | +46% |
| Driehaus Capital Management LLC | 450,045 | 3.12% | $5.9M | No change |
| TCG Crossover Management, LLC | 416,301 | 2.89% | $5.5M | No change |
| Kalehua Capital Management LLC | 405,040 | 2.81% | $5.3M | +270% |
| Siren, L.L.C. | 347,718 | 2.41% | $4.6M | No change |
| AQR Capital Management LLC | 298,974 | 2.07% | $3.9M | +12% |
| Geode Capital Management, LLC | 296,870 | 2.06% | $3.9M | +71% |
| 72 Investment Holdings, LLC | 276,831 | 1.92% | $3.6M | No change |
| State Street Corp | 232,587 | 1.61% | $3.1M | +66% |
| Vanguard Portfolio Management LLC | 223,551 | 1.55% | $2.9M | +50% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, KRRO insiders reported $3.3M of open-market purchases and $6.7M of sales. 92% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Jean Francois Formela | Director | Sale plan | 33,175 | $14.30 | $474K | Form 4 |
| Nov 12, 2026 | Jean Francois Formela | Director | Sale plan | 6,870 | $14.30 | $98.2K | Form 4 |
| Nov 11, 2026 | Jean Francois Formela | Director | Sale plan | 19,042 | $15.00 | $286K | Form 4 |
| Nov 11, 2026 | Jean Francois Formela | Director | Sale plan | 2,984 | $15.60 | $46.6K | Form 4 |
| Nov 11, 2026 | Jean Francois Formela | Director | Sale plan | 3,944 | $15.00 | $59.2K | Form 4 |
| Nov 11, 2026 | Jean Francois Formela | Director | Sale plan | 617 | $15.60 | $9.6K | Form 4 |
| Oct 26, 2026 | Lynx1 Capital Management LP +1 | 10% owner | Purchase | 25,124 | $11.75 | $295K | Form 4 |
| Oct 23, 2026 | Lynx1 Capital Management LP +1 | 10% owner | Purchase | 2,510 | $12.11 | $30.4K | Form 4 |
| Oct 22, 2026 | Lynx1 Capital Management LP +1 | 10% owner | Purchase | 12,175 | $9.68 | $118K | Form 4 |
| Oct 22, 2026 | Lynx1 Capital Management LP +1 | 10% owner | Purchase | 40,000 | $11.04 | $441K | Form 4 |
| Sep 14, 2026 | Jean Francois Formela | Director | Sale plan | 31,888 | $14.12 | $450K | Form 4 |
| Sep 14, 2026 | Jean Francois Formela | Director | Sale plan | 6,602 | $14.12 | $93.2K | Form 4 |
| Sep 11, 2026 | Jean Francois Formela | Director | Sale plan | 1,750 | $13.99 | $24.5K | Form 4 |
| Sep 11, 2026 | Jean Francois Formela | Director | Sale plan | 8,450 | $13.99 | $118K | Form 4 |
| Sep 11, 2026 | Oliver Dolan | Vice president | Sale | 5 | $13.72 | $69 | Form 4 |
| Sep 9, 2026 | Oliver Dolan | Vice president | Sale | 6 | $13.60 | $82 | Form 4 |
| Sep 8, 2026 | Oliver Dolan | Vice president | Sale | 7,347 | $13.51 | $99.3K | Form 4 |
| Aug 26, 2026 | Jean Francois Formela | Director | Sale plan | 249 | $13.96 | $3.5K | Form 4 |
| Aug 26, 2026 | Jean Francois Formela | Director | Sale plan | 51 | $13.96 | $712 | Form 4 |
| Aug 19, 2026 | Jean Francois Formela | Director | Sale plan | 23,584 | $14.00 | $330K | Form 4 |
| Aug 19, 2026 | Jean Francois Formela | Director | Sale plan | 4,884 | $14.00 | $68.4K | Form 4 |
| Aug 11, 2026 | Jean Francois Formela | Director | Sale plan | 1,775 | $13.96 | $24.8K | Form 4 |
| Aug 11, 2026 | Jean Francois Formela | Director | Sale plan | 368 | $13.96 | $5.1K | Form 4 |
| Aug 10, 2026 | Lynx1 Capital Management LP +1 | 10% owner | Purchase | 1,462 | $13.19 | $19.3K | Form 4 |
| Aug 6, 2026 | Lynx1 Capital Management LP +1 | 10% owner | Purchase | 5,222 | $11.40 | $59.5K | Form 4 |
| Aug 4, 2026 | Ram Aiyar | CEO | Sale | 5,802 | $10.84 | $62.9K | Form 4 |
| Jul 6, 2026 | Jean Francois Formela | Director | Sale plan | 817 | $13.96 | $11.4K | Form 4 |
| Jul 6, 2026 | Jean Francois Formela | Director | Sale plan | 8,506 | $13.96 | $119K | Form 4 |
| Jul 2, 2026 | Jean Francois Formela | Director | Sale plan | 85,955 | $14.03 | $1.2M | Form 4 |
| Jul 2, 2026 | Jean Francois Formela | Director | Sale plan | 14,745 | $14.03 | $207K | Form 4 |
| Jun 24, 2026 | Jean Francois Formela | Director | Sale plan | 40,679 | $14.60 | $594K | Form 4 |
| Jun 24, 2026 | Jean Francois Formela | Director | Sale plan | 114 | $14.98 | $1.7K | Form 4 |
| Jun 24, 2026 | Jean Francois Formela | Director | Sale plan | 666 | $14.98 | $10K | Form 4 |
| Jun 24, 2026 | Jean Francois Formela | Director | Sale plan | 6,979 | $14.60 | $102K | Form 4 |
| Jun 23, 2026 | Jean Francois Formela | Director | Sale plan | 101,579 | $14.25 | $1.4M | Form 4 |
| Jun 23, 2026 | Jean Francois Formela | Director | Sale plan | 17,426 | $14.25 | $248K | Form 4 |
| Jun 22, 2026 | Jean Francois Formela | Director | Sale plan | 3,382 | $13.95 | $47.2K | Form 4 |
| Jun 22, 2026 | Jean Francois Formela | Director | Sale plan | 580 | $13.95 | $8.1K | Form 4 |
| Jun 16, 2026 | Todd Chappell | Chief Operating Officer | Sale | 3,168 | $10.83 | $34.3K | Form 4 |
| Jun 16, 2026 | Loic A Vincent | Chief Scientific Officer | Sale | 3,418 | $10.83 | $37K | Form 4 |
| Jun 16, 2026 | Jeffrey Cerio | General Counsel | Sale | 6,609 | $10.83 | $71.6K | Form 4 |
| Jun 16, 2026 | Oliver Dolan | Vice president | Sale | 3,383 | $10.83 | $36.6K | Form 4 |
| May 29, 2026 | Ram Aiyar | CEO | Sale | 15,152 | $12.98 | $197K | Form 4 |
| May 28, 2026 | Jean Francois Formela | Director | Sale plan | 2,441 | $13.95 | $34.1K | Form 4 |
| May 28, 2026 | Jean Francois Formela | Director | Sale plan | 419 | $13.95 | $5.8K | Form 4 |
| Mar 31, 2026 | Weston Nichols +1 | 10% owner | Purchase | 520 | $10.60 | $5.5K | Form 4 |
| Mar 10, 2026 | Rick Yang | 10% owner | Purchase | 207,100 | $11.11 | $2.3M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jean Francois Formela | Director | – | $6.1M | Nov 12, 2026 |
| Rick Yang | 10% owner | $2.3M | – | Mar 10, 2026 |
| Lynx1 Capital Management LP | 10% owner | $964K | – | Oct 26, 2026 |
| Ram Aiyar | President and CEO, Director | – | $260K | Aug 4, 2026 |
| Oliver Dolan | Senior Vice President, Finance | – | $136K | Sep 11, 2026 |
| Jeffrey Cerio | General Counsel | – | $71.6K | Jun 16, 2026 |
| Loic A Vincent | Chief Scientific Officer | – | $37K | Jun 16, 2026 |
| Todd Chappell | Chief Operating Officer | – | $34.3K | Jun 16, 2026 |
| Weston Nichols | 10% owner | $5.5K | – | Mar 31, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KRRO short interest
High short interest. 11.9% of KRRO shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 46%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.75M KRRO shares were sold short, 11.9% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 213,901 shares, buying them all back would take about 8.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.75M | 11.88% | +1% | 213,901 | 8.2 |
| Oct 15, 2026 | 1.73M | 11.77% | +3% | 179,986 | 9.6 |
| Sep 30, 2026 | 1.68M | 11.38% | +8% | 255,628 | 6.5 |
| Sep 15, 2026 | 1.55M | 10.54% | +5% | 130,312 | 11.9 |
| Aug 31, 2026 | 1.48M | 10.08% | -2% | 71,165 | 20.9 |
| Aug 14, 2026 | 1.51M | 10.27% | +5% | 105,843 | 14.3 |
| Jul 31, 2026 | 1.44M | 9.97% | -1% | 157,016 | 9.2 |
| Jul 15, 2026 | 1.46M | 10.12% | -14% | 229,522 | 6.4 |
| Jun 30, 2026 | 1.71M | 11.82% | +29% | 367,177 | 4.6 |
| Jun 15, 2026 | 1.32M | 9.15% | +4% | 144,447 | 9.1 |
| May 29, 2026 | 1.27M | 8.77% | +6% | 166,458 | 7.6 |
| May 15, 2026 | 1.19M | 8.28% | +7% | 104,312 | 11.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Korro Bio company events
Korro Bio filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AgreementEnded an important agreement. Filing
- Oct 22, 2026AnnouncementKorro Bio, Inc. issued a press release announcing preclinical results for KRRO-111, its development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency. Filing
- Oct 5, 2026AnnouncementKorro Bio, Inc. issued a press release announcing that it has dosed the first cohort of participants in ANCHOR, its Phase 1/2 clinical trial of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with urea cycle… Filing
- Aug 19, 2026AnnouncementKorro Bio, Inc., or Korro, announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with… Filing
- Aug 6, 2026AgreementKorro Bio, Inc., or Korro, entered into an exchange agreement with entities affiliated with Venrock Healthcare Capital Partners, together VenRock, pursuant to which (i) VenRock agreed to surrender an aggregate of 1,000,000 shares of Korro’s common stock, par value $0.001 per share, for no… Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- May 19, 2026AnnouncementKorro Bio, Inc. issued a press release announcing the addition of KRRO-111 for the potential treatment of Alpha-1 Antitrypsin Deficiency to its pipeline of therapeutic programs in development. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AgreementKorro Bio, Inc., or Korro, entered into a subscription agreement with a number of institutional accredited investors pursuant to which it agreed to sell and issue in a private placement pursuant to the exemption in Section 4(a)(2) of the Securities Act of 1933, as amended, or the 1933 Act: (i) an… Filing
- Jan 27, 2026AnnouncementKorro Bio, Inc. hosted a virtual Analyst Day. Filing
- Jan 15, 2026AnnouncementKorro Bio, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. Filing
- Dec 18, 2025LeadershipKorro Bio, Inc., or Korro, entered into an amended and restated employment agreement with Jeffrey Cerio, which amended and restated his employment agreement dated August 28, 2024. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Korro Bio financials
Famous investors that hold KRRO
2 of the 50 well-known investors we track reported holding KRRO in their latest 13F filing. The largest position is Jim Simons's, worth $651K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 65,662 | $651K | 0.0% | -41% |
| Israel Englander · Millennium Management | Q3 2026 | 60,000 | $595K | 0.0% | -49% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named KRRO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 5.9% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 5.9% |
| Nov 16, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.9% |
| Nov 16, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.9% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G | 6.8% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G | 6.8% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 4.9% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 4.9% |
Questions about Korro Bio, Inc. (KRRO) stock
Who owns the most KRRO stock?
The largest reported owner of Korro Bio, Inc. (KRRO) is Lynx1 Capital Management LP, with 10.7% of the company. In total, 107 funds and institutions reported holding KRRO at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are KRRO insiders buying or selling?
In the last 12 months, KRRO insiders reported 8 open-market purchases worth $3.3M and 39 sales worth $6.7M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in KRRO?
As of Oct 30, 2026, 1.75M KRRO shares were sold short, 11.9% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 213,901 shares, buying them all back would take about 8.2 trading days (days to cover). See the history.
Which famous investors hold KRRO?
2 of the 50 well-known investors we track reported KRRO in their latest 13F filing, including Jim Simons, Israel Englander. The largest position is worth $651K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.